ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
447 | (±¹¿Ü)SCI | National trends in the prevalence of hepatitis B and C in South Korea, before and during COVID-19 pandemic (2007-2021); a nationwide representative study |
446 | (±¹¿Ü)SCI | Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease |
445 | (±¹¿Ü)SCI | Comparison of Physician-Controlled Maneuver and Assistant-Controlled Maneuver during Endoscopic Retrograde Cholangiopancreatography |
444 | (±¹¿Ü)SCI | Randomized trial of prophylactic antibiotics for endoscopic retrograde cholangiopancreatography in patients with biliary obstruction |
443 | (±¹¿Ü)SCI | Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients |
442 | (±¹¿Ü)SCI | The Diagnostic Performance of Linked Color Imaging Compared to White Light Imaging in Endoscopic Diagnosis of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis |
441 | (±¹¿Ü)SCI | Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study |
440 | (±¹¿Ü)SCI | Efficacy of a Newly Developed Guidewire for Selective BiliaryCannulation: A Multicenter Randomized Controlled Trial |
439 | (±¹¿Ü)SCI | Is it enough to observe less than 2 cm sized gastric SET? |
438 | (±¹¿Ü)SCI | Evaluation of the Efficacy and Safety of DW1903 in Patients withGastritis: A Randomized, Double-Blind, Noninferiority, Multicenter,Phase 3 study |
Copyright ¨Ï chamc, All rights reserved.